Saturday, May 27, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Medical Countermeasures

InBios, UN-Reno Partner to Develop Diagnostic for Melioidosis

by Global Biodefense Staff
August 9, 2012

The National Institute of Allergy and Infectious Diseases (NIAID) has awarded a grant to researchers at the University of Nevada, Reno and their collaborator, InBios International of Seattle, to further development of a rapid diagnostic for melioidosis.

Also known as Whitmore’s disease, melioidosis is a difficult to treat infection caused by Burkholderia pseudomallei, a Category B biothreat as classified by the Centers for Disease Control and Prevention.

Melioidosis is predominately a disease of tropical climates, especially in Southeast Asia and northern Australia where it is widespread. The B. pseudomallei bacteria causing melioidosis are found in contaminated water and soil. It is spread to humans and animals through direct contact with the contaminated source, is easily aerosolized and has a high mortality rate.

With NIAID’s two-year Phase I Small Business Technology Transfer (STTR) grant, the recipients will further development of their Active Melioidosis Detect (AMD) test.

“Results so far are very encouraging,” said David AuCoin, Principle Investigator at the Diagnostics Discovery Laboratory, University of Nevada School of Medicine. “We have a prototype of the product in Thailand and Australia now, regions that are hardest hit, to evaluate its effectiveness in endemic settings.”

Currently, there are no validated diagnostic products for melioidosis, and patient samples must be cultured, taking three to seven days to diagnose the disease. “Unfortunately, melioidosis can kill you well before the diagnosis is confirmed,” said AuCoin.

AuCoin produced and has been working with the monoclonal antibody used in the test since 2009. The work is also partially funded by the Pacific Southwest Regional Center for Excellence in Biodefense and Emerging Infections.

The team is working to secure Phase II funding following the two years of Phase I work, which will allow another three years of product development to generate the necessary preclinical studies to submit an application to the FDA for approval to distribute the assay.

Source: UN-Reno

Tags: AwardsBurkholderia

Related Posts

Vials of finished vaccines
Funding News

UK Biomanufacturing Fund to Bolster Supply Chain Resilience and Pandemic Preparedness

May 26, 2023
Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics
Industry News

Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

April 20, 2023
Medical Countermeasures

Scientists Design Molecule to Slow SARS-Cov-2 Infection

March 29, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions
Pathogens

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Load More

Latest News

Vials of finished vaccines

UK Biomanufacturing Fund to Bolster Supply Chain Resilience and Pandemic Preparedness

May 26, 2023
Dr. Sen Pei Discusses Challenges in Forecasting Antimicrobial Resistance

Dr. Sen Pei Discusses Challenges in Forecasting Antimicrobial Resistance

April 26, 2023
Biodefense Headlines – 25 April 2023

Biodefense Headlines – 25 April 2023

April 25, 2023
Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

April 20, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2023 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2023 Stemar Media Group LLC